Human Brain Cancer Peripheral Blood Mononuclear Cells

Description

Human Brain Cancer Peripheral Blood Mononuclear Cells (PBMCs) are isolated from patients with primary (glioblastoma, astrocytoma) or metastatic brain malignancies, providing researchers with critical insights into the systemic immune response to intracranial tumors. These human-derived PBMCs contain lymphocytes (T cells, B cells, NK cells) and monocytes that exhibit brain tumor-specific immune alterations, including elevated exhausted PD-1⁺CD8⁺ T cells and increased myeloid-derived suppressor cells (CD33⁺HLA-DR⁻), reflecting the profound immunosuppression characteristic of the brain tumor microenvironment. The cells display typical mononuclear morphology with intact surface markers and maintain functional cytokine production (TGF-β, IL-10) in response to tumor antigens. They are particularly valuable for studying the unique challenges of brain tumor immunology, including the blood-brain barrier’s restriction on immune cell trafficking and tumor-associated immunosuppression. These PBMCs provide a vital platform for evaluating inflammation markers in brain cancer, studying adaptive immunity in brain cancer, performing PBMC profiling brain cancer, and understanding the overall brain tumor immune response.

Application

• Human Brain Cancer Peripheral Blood Mononuclear Cells can be used for immunotherapy research, such as in vitro expansion and functional evaluation of CAR-T cell therapy, or target screening to enhance anti-tumor immune responses. In addition, immunophenotyping of PBMCs (such as PD-1 and CTLA-4 expression levels) can assess the patient’s immunosuppressive status and guide immune checkpoint inhibitor therapy.